Webinar : US Market Access: “Who Pays? “comes first

Quand :
29 septembre 2020 @ 17 h 00 min – 18 h 00 min
2020-09-29T17:00:00+02:00
2020-09-29T18:00:00+02:00
Coût :
Gratuit
Contact :

While the US Markets for medical technologies is the largest in the world, it is probably the most complex when it comes to the practical monetization of novel technologies. Even before:

  • clinical validation plans are made,
  • FDA trajectories are explored,
  • or KOL recruited,

the Board (and in particular the CEO) of any entrepreneurial healthcare company must be able to answer and substantiate two questions: Who will pay for my solution? and how much?

An educated answer will earn the trust of financial partners and crystalize a go-to-market strategy.

In this 45 minutes webi-seminar, Dr. Mathieu Petitjean, +20 years US veteran, advisor and entrepreneur will give a high level overview of three pivotal US-centric economic models including Reimbursement, Cost-Benefit and Cost-effectiveness models. He will discuss how they each should be activated to support  or define a market access plan. Each will be illustrated by a case study. The webinar will also present the Soft Landing Program proposed by big bang factory to further develop a practical understanding of such models, and more.

WEBINAR

From 17h00 to 18h00

REGISTRATION

Compulsory registration until 28th September 2020

SPEAKERS

Marie Buhot-Launay, Founding Partner, big bang factory

Marie is passionate about bringing pioneering products to a new market. For the past 9 years, Marie has supported over 60 innovative companies in their U.S. launch, with a specific focus on sales and marketing.

 

 

Dr Mathieu Petitjean, President, Mednest

20+ years US veteran, advisor and entrepreneur, Mathieu Petitjean is an experienced operational leader with 25 years of executive-level and international business experience in Healthcare Diagnostics and Medical Technology.

 

PARTICIPATION COSTS
Free

CONTACT
Linda HAOUCINE
Communication manager
linda.haoucine@medicalps.eu
0476549563

0 réponses

Laisser un commentaire

Participez-vous à la discussion?
N'hésitez pas à contribuer!

Laisser un commentaire

Votre adresse de messagerie ne sera pas publiée. Les champs obligatoires sont indiqués avec *